(S)-3-(4-bromo-2,5-dimethoxyphenyl)piperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-3-(4-bromo-2,5-dimethoxyphenyl)piperidine
• 英文别名: (S)-3-(4-Bromo-2,5-dimethoxyphenyl)piperidine；(3S)-3-(4-bromo-2,5-dimethoxyphenyl)piperidine
• 化学式: C₁₃H₁₈BrNO₂
• 分子量: 300.195
• InChiKey: ULJHXMHMDJQESG-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
  申请人：Lophora ApS

  公开号：US20210137908A1

  公开（公告）日：2021-05-13

  The present invention relates to agonists of the 5-HT 2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT 2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT 2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT 2A /5-HT 2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT 2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT 2A agonist for the use in the treatment of treatment-resistant depression.

  本发明涉及5-HT2A 5-羟色胺受体的激动剂及其医疗用途。在一个方面，本发明涉及式(I)的5-HT2A激动剂。在第二个方面，本发明涉及式(II)的选择性5-HT2A激动剂。在另一个方面，本发明涉及式(III)的混合5-HT2A/5-HT2C激动剂。在另一个方面，本发明涉及用于治疗抑郁症的5-HT2A激动剂，更具体地说是用于治疗难治性抑郁症的5-HT2A激动剂。
• 5-HT2A agonists for use in treatment of depression
  申请人：Lophora ApS

  公开号：US11246860B2

  公开（公告）日：2022-02-15

  The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.

  本发明涉及 5-HT2A 血清素受体的激动剂及其医疗用途。一方面，本发明涉及式（I）的 5-HT2A 激动剂。第二方面，本发明涉及式（II）的选择性 5-HT2A 激动剂。另一方面，本发明涉及式（III）的 5-HT2A/5-HT2C 混合激动剂。再一方面，本发明涉及用于治疗抑郁障碍的5-HT2A激动剂，尤其是用于治疗耐药抑郁症的5-HT2A激动剂。